Who are MVC-COV1901(3 Months)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Spikevax bivalent Original/Omicron BA.1, CCP, protein subunit: Novavax COVID-19 vaccine, batch 3 of Ad5-nCoV, Ad26.COV2.S vaccine, COVAX only (1st and 2nd dose).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mvc-cov1901-3-months.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

MVC-COV1901(3 Months) — Competitive Intelligence Brief

MVC-COV1901(3 Months) (MVC-COV1901(3 Months)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Protein subunit vaccine. Area: Immunology / Infectious Disease.

marketed Protein subunit vaccine SARS-CoV-2 spike protein Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

MVC-COV1901(3 Months) (MVC-COV1901(3 Months)) — Taoyuan General Hospital. MVC-COV1901 is a recombinant protein subunit vaccine that stimulates immune responses against SARS-CoV-2 spike protein to prevent COVID-19 infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
MVC-COV1901(3 Months) TARGET	MVC-COV1901(3 Months)	Taoyuan General Hospital	marketed	Protein subunit vaccine	SARS-CoV-2 spike protein
Spikevax bivalent Original/Omicron BA.1	Spikevax bivalent Original/Omicron BA.1	Jules Bordet Institute	marketed	mRNA vaccine	SARS-CoV-2 spike protein (original strain and Omicron BA.1 variant)
CCP	CCP	Metro Infectious Disease Consultants	marketed	Convalescent plasma	SARS-CoV-2 spike protein and other viral antigens
protein subunit: Novavax COVID-19 vaccine	protein subunit: Novavax COVID-19 vaccine	Novavax	marketed	Protein subunit vaccine	SARS-CoV-2 spike protein
batch 3 of Ad5-nCoV	batch 3 of Ad5-nCoV	Jiangsu Province Centers for Disease Control and Prevention	marketed	viral vector vaccine	SARS-CoV-2 spike protein
Ad26.COV2.S vaccine	Ad26.COV2.S vaccine	University Medical Center Groningen	marketed	viral vector vaccine	SARS-CoV-2 spike protein
COVAX only (1st and 2nd dose)	COVAX only (1st and 2nd dose)	China National Biotec Group Company Limited	marketed	Inactivated viral vaccine	SARS-CoV-2 spike protein and other viral antigens

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Protein subunit vaccine class)

Novavax · 2 drugs in this class
Taoyuan General Hospital · 2 drugs in this class
Medigen Vaccine Biologics Corp. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MVC-COV1901(3 Months) — Competitive Intelligence Brief. https://druglandscape.com/ci/mvc-cov1901-3-months. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab